End points in dermatologic clinical trials: A review for clinicians

Erin X. Wei, Robert S. Kirsner, William H. Eaglstein

Research output: Contribution to journalReview articlepeer-review

8 Scopus citations


Clinical trials are critical for the development of new therapies in dermatology, and their results help determine US Food and Drug Administration (FDA) approval and guide care. Of special relevance is the clinical trial efficacy end point, the metric from which statistically significant outcome is derived. Clinicians' understanding of a clinical trial's end point is necessary for critical analysis of the trial results and for applying those results to daily practice. This review provides practical knowledge and critical evaluation of end points used in treatment approvals by the FDA. The end points for actinic keratosis, acne vulgaris, atopic dermatitis, onychomycosis, and cutaneous ulcer serve as examples.

Original languageEnglish (US)
Pages (from-to)203-209
Number of pages7
JournalJournal of the American Academy of Dermatology
Issue number1
StatePublished - Jul 1 2016


  • Acne vulgaris
  • Actinic keratosis
  • Atopic dermatitis
  • Clinical trials
  • Cutaneous wounds
  • End points
  • Onychomycosis
  • Randomized controlled trials
  • Wound healing

ASJC Scopus subject areas

  • Dermatology


Dive into the research topics of 'End points in dermatologic clinical trials: A review for clinicians'. Together they form a unique fingerprint.

Cite this